1 Neuroblastoma Chemotherapy Drugs Market Overview 1.1 Product Overview and Scope of Neuroblastoma Chemotherapy Drugs 1.2 Neuroblastoma Chemotherapy Drugs Segment by Type 1.2.1 Global Neuroblastoma Chemotherapy Drugs Market Value Comparison by Type (2023-2029) 1.2.2 Cyclophosphamide 1.2.3 Cisplatin or Carboplatin 1.2.4 Vincristine 1.2.5 Doxorubicin (Adriamycin) 1.2.6 Etoposide 1.2.7 Other 1.3 Neuroblastoma Chemotherapy Drugs Segment by Application 1.3.1 Global Neuroblastoma Chemotherapy Drugs Market Value by Application: (2023-2029) 1.3.2 Hospital 1.3.3 Clinic 1.3.4 Other 1.4 Global Neuroblastoma Chemotherapy Drugs Market Size Estimates and Forecasts 1.4.1 Global Neuroblastoma Chemotherapy Drugs Revenue 2018-2029 1.4.2 Global Neuroblastoma Chemotherapy Drugs Sales 2018-2029 1.4.3 Global Neuroblastoma Chemotherapy Drugs Market Average Price (2018-2029) 1.5 Assumptions and Limitations 2 Neuroblastoma Chemotherapy Drugs Market Competition by Manufacturers 2.1 Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Manufacturers (2018-2023) 2.2 Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Manufacturers (2018-2023) 2.3 Global Neuroblastoma Chemotherapy Drugs Average Price by Manufacturers (2018-2023) 2.4 Global Neuroblastoma Chemotherapy Drugs Industry Ranking 2021 VS 2022 VS 2023 2.5 Global Key Manufacturers of Neuroblastoma Chemotherapy Drugs, Manufacturing Sites & Headquarters 2.6 Global Key Manufacturers of Neuroblastoma Chemotherapy Drugs, Product Type & Application 2.7 Neuroblastoma Chemotherapy Drugs Market Competitive Situation and Trends 2.7.1 Neuroblastoma Chemotherapy Drugs Market Concentration Rate 2.7.2 The Global Top 5 and Top 10 Largest Neuroblastoma Chemotherapy Drugs Players Market Share by Revenue 2.7.3 Global Neuroblastoma Chemotherapy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.8 Manufacturers Mergers & Acquisitions, Expansion Plans 3 Neuroblastoma Chemotherapy Drugs Retrospective Market Scenario by Region 3.1 Global Neuroblastoma Chemotherapy Drugs Market Size by Region: 2018 Versus 2022 Versus 2029 3.2 Global Neuroblastoma Chemotherapy Drugs Global Neuroblastoma Chemotherapy Drugs Sales by Region: 2018-2029 3.2.1 Global Neuroblastoma Chemotherapy Drugs Sales by Region: 2018-2023 3.2.2 Global Neuroblastoma Chemotherapy Drugs Sales by Region: 2024-2029 3.3 Global Neuroblastoma Chemotherapy Drugs Global Neuroblastoma Chemotherapy Drugs Revenue by Region: 2018-2029 3.3.1 Global Neuroblastoma Chemotherapy Drugs Revenue by Region: 2018-2023 3.3.2 Global Neuroblastoma Chemotherapy Drugs Revenue by Region: 2024-2029 3.4 North America Neuroblastoma Chemotherapy Drugs Market Facts & Figures by Country 3.4.1 North America Neuroblastoma Chemotherapy Drugs Market Size by Country: 2018 VS 2022 VS 2029 3.4.2 North America Neuroblastoma Chemotherapy Drugs Sales by Country (2018-2029) 3.4.3 North America Neuroblastoma Chemotherapy Drugs Revenue by Country (2018-2029) 3.4.4 U.S. 3.4.5 Canada 3.5 Europe Neuroblastoma Chemotherapy Drugs Market Facts & Figures by Country 3.5.1 Europe Neuroblastoma Chemotherapy Drugs Market Size by Country: 2018 VS 2022 VS 2029 3.5.2 Europe Neuroblastoma Chemotherapy Drugs Sales by Country (2018-2029) 3.5.3 Europe Neuroblastoma Chemotherapy Drugs Revenue by Country (2018-2029) 3.5.4 Germany 3.5.5 France 3.5.6 U.K. 3.5.7 Italy 3.5.8 Russia 3.6 Asia Pacific Neuroblastoma Chemotherapy Drugs Market Facts & Figures by Country 3.6.1 Asia Pacific Neuroblastoma Chemotherapy Drugs Market Size by Country: 2018 VS 2022 VS 2029 3.6.2 Asia Pacific Neuroblastoma Chemotherapy Drugs Sales by Country (2018-2029) 3.6.3 Asia Pacific Neuroblastoma Chemotherapy Drugs Revenue by Country (2018-2029) 3.6.4 China 3.6.5 Japan 3.6.6 South Korea 3.6.7 India 3.6.8 Australia 3.6.9 Taiwan 3.6.10 Indonesia 3.6.11 Thailand 3.6.12 Malaysia 3.6.13 Philippines 3.7 Latin America Neuroblastoma Chemotherapy Drugs Market Facts & Figures by Country 3.7.1 Latin America Neuroblastoma Chemotherapy Drugs Market Size by Country: 2018 VS 2022 VS 2029 3.7.2 Latin America Neuroblastoma Chemotherapy Drugs Sales by Country (2018-2029) 3.7.3 Latin America Neuroblastoma Chemotherapy Drugs Revenue by Country (2018-2029) 3.7.4 Mexico 3.7.5 Brazil 3.7.6 Argentina 3.8 Middle East and Africa Neuroblastoma Chemotherapy Drugs Market Facts & Figures by Country 3.8.1 Middle East and Africa Neuroblastoma Chemotherapy Drugs Market Size by Country: 2018 VS 2022 VS 2029 3.8.2 Middle East and Africa Neuroblastoma Chemotherapy Drugs Sales by Country (2018-2029) 3.8.3 Middle East and Africa Neuroblastoma Chemotherapy Drugs Revenue by Country (2018-2029) 3.8.4 Turkey 3.8.5 Saudi Arabia 3.8.6 U.A.E 4 Segment by Type 4.1 Global Neuroblastoma Chemotherapy Drugs Sales by Type (2018-2029) 4.1.1 Global Neuroblastoma Chemotherapy Drugs Sales by Type (2018-2023) 4.1.2 Global Neuroblastoma Chemotherapy Drugs Sales by Type (2024-2029) 4.1.3 Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2018-2029) 4.2 Global Neuroblastoma Chemotherapy Drugs Revenue by Type (2018-2029) 4.2.1 Global Neuroblastoma Chemotherapy Drugs Revenue by Type (2018-2023) 4.2.2 Global Neuroblastoma Chemotherapy Drugs Revenue by Type (2024-2029) 4.2.3 Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Type (2018-2029) 4.3 Global Neuroblastoma Chemotherapy Drugs Price by Type (2018-2029) 5 Segment by Application 5.1 Global Neuroblastoma Chemotherapy Drugs Sales by Application (2018-2029) 5.1.1 Global Neuroblastoma Chemotherapy Drugs Sales by Application (2018-2023) 5.1.2 Global Neuroblastoma Chemotherapy Drugs Sales by Application (2024-2029) 5.1.3 Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2018-2029) 5.2 Global Neuroblastoma Chemotherapy Drugs Revenue by Application (2018-2029) 5.2.1 Global Neuroblastoma Chemotherapy Drugs Revenue by Application (2018-2023) 5.2.2 Global Neuroblastoma Chemotherapy Drugs Revenue by Application (2024-2029) 5.2.3 Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Application (2018-2029) 5.3 Global Neuroblastoma Chemotherapy Drugs Price by Application (2018-2029) 6 Key Companies Profiled 6.1 Baxter Healthcare 6.1.1 Baxter Healthcare Corporation Information 6.1.2 Baxter Healthcare Description and Business Overview 6.1.3 Baxter Healthcare Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2018-2023) 6.1.4 Baxter Healthcare Neuroblastoma Chemotherapy Drugs Product Portfolio 6.1.5 Baxter Healthcare Recent Developments/Updates 6.2 Ingenus Pharmaceuticals 6.2.1 Ingenus Pharmaceuticals Corporation Information 6.2.2 Ingenus Pharmaceuticals Description and Business Overview 6.2.3 Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2018-2023) 6.2.4 Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Portfolio 6.2.5 Ingenus Pharmaceuticals Recent Developments/Updates 6.3 ANI Pharmaceuticals 6.3.1 ANI Pharmaceuticals Corporation Information 6.3.2 ANI Pharmaceuticals Description and Business Overview 6.3.3 ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2018-2023) 6.3.4 ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Portfolio 6.3.5 ANI Pharmaceuticals Recent Developments/Updates 6.4 Teva Pharmaceuticals 6.4.1 Teva Pharmaceuticals Corporation Information 6.4.2 Teva Pharmaceuticals Description and Business Overview 6.4.3 Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2018-2023) 6.4.4 Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Portfolio 6.4.5 Teva Pharmaceuticals Recent Developments/Updates 6.5 Qilu Pharmaceutical 6.5.1 Qilu Pharmaceutical Corporation Information 6.5.2 Qilu Pharmaceutical Description and Business Overview 6.5.3 Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2018-2023) 6.5.4 Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Product Portfolio 6.5.5 Qilu Pharmaceutical Recent Developments/Updates 6.6 Pfizer 6.6.1 Pfizer Corporation Information 6.6.2 Pfizer Description and Business Overview 6.6.3 Pfizer Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2018-2023) 6.6.4 Pfizer Neuroblastoma Chemotherapy Drugs Product Portfolio 6.6.5 Pfizer Recent Developments/Updates 6.7 Hikma Pharmaceuticals 6.6.1 Hikma Pharmaceuticals Corporation Information 6.6.2 Hikma Pharmaceuticals Description and Business Overview 6.6.3 Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2018-2023) 6.4.4 Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Portfolio 6.7.5 Hikma Pharmaceuticals Recent Developments/Updates 6.8 Fresenius Kabi 6.8.1 Fresenius Kabi Corporation Information 6.8.2 Fresenius Kabi Description and Business Overview 6.8.3 Fresenius Kabi Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2018-2023) 6.8.4 Fresenius Kabi Neuroblastoma Chemotherapy Drugs Product Portfolio 6.8.5 Fresenius Kabi Recent Developments/Updates 6.9 Accord Healthcare 6.9.1 Accord Healthcare Corporation Information 6.9.2 Accord Healthcare Description and Business Overview 6.9.3 Accord Healthcare Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2018-2023) 6.9.4 Accord Healthcare Neuroblastoma Chemotherapy Drugs Product Portfolio 6.9.5 Accord Healthcare Recent Developments/Updates 6.10 Viatris 6.10.1 Viatris Corporation Information 6.10.2 Viatris Description and Business Overview 6.10.3 Viatris Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2018-2023) 6.10.4 Viatris Neuroblastoma Chemotherapy Drugs Product Portfolio 6.10.5 Viatris Recent Developments/Updates 7 Industry Chain and Sales Channels Analysis 7.1 Neuroblastoma Chemotherapy Drugs Industry Chain Analysis 7.2 Neuroblastoma Chemotherapy Drugs Key Raw Materials 7.2.1 Key Raw Materials 7.2.2 Raw Materials Key Suppliers 7.3 Neuroblastoma Chemotherapy Drugs Production Mode & Process 7.4 Neuroblastoma Chemotherapy Drugs Sales and Marketing 7.4.1 Neuroblastoma Chemotherapy Drugs Sales Channels 7.4.2 Neuroblastoma Chemotherapy Drugs Distributors 7.5 Neuroblastoma Chemotherapy Drugs Customers 8 Neuroblastoma Chemotherapy Drugs Market Dynamics 8.1 Neuroblastoma Chemotherapy Drugs Industry Trends 8.2 Neuroblastoma Chemotherapy Drugs Market Drivers 8.3 Neuroblastoma Chemotherapy Drugs Market Challenges 8.4 Neuroblastoma Chemotherapy Drugs Market Restraints 9 Research Finding and Conclusion 10 Methodology and Data Source 10.1 Methodology/Research Approach 10.1.1 Research Programs/Design 10.1.2 Market Size Estimation 10.1.3 Market Breakdown and Data Triangulation 10.2 Data Source 10.2.1 Secondary Sources 10.2.2 Primary Sources 10.3 Author List 10.4 Disclaimer

List of Tables Table 1. Global Neuroblastoma Chemotherapy Drugs Market Value Comparison by Type (2023-2029) & (US$ Million) Table 2. Global Neuroblastoma Chemotherapy Drugs Market Value Comparison by Application (2023-2029) & (US$ Million) Table 3. Global Neuroblastoma Chemotherapy Drugs Market Competitive Situation by Manufacturers in 2022 Table 4. Global Neuroblastoma Chemotherapy Drugs Sales (K Units) of Key Manufacturers (2018-2023) Table 5. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Manufacturers (2018-2023) Table 6. Global Neuroblastoma Chemotherapy Drugs Revenue (US$ Million) by Manufacturers (2018-2023) Table 7. Global Neuroblastoma Chemotherapy Drugs Revenue Share by Manufacturers (2018-2023) Table 8. Global Market Neuroblastoma Chemotherapy Drugs Average Price (US$/Unit) of Key Manufacturers (2018-2023) Table 9. Global Key Players of Neuroblastoma Chemotherapy Drugs, Industry Ranking, 2021 VS 2022 VS 2023 Table 10. Global Key Manufacturers of Neuroblastoma Chemotherapy Drugs, Manufacturing Sites & Headquarters Table 11. Global Key Manufacturers of Neuroblastoma Chemotherapy Drugs, Product Type & Application Table 12. Global Key Manufacturers of Neuroblastoma Chemotherapy Drugs, Date of Enter into This Industry Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 14. Global Neuroblastoma Chemotherapy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroblastoma Chemotherapy Drugs as of 2022) Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans Table 16. Global Neuroblastoma Chemotherapy Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029 Table 17. Global Neuroblastoma Chemotherapy Drugs Sales by Region (2018-2023) & (K Units) Table 18. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Region (2018-2023) Table 19. Global Neuroblastoma Chemotherapy Drugs Sales by Region (2024-2029) & (K Units) Table 20. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Region (2024-2029) Table 21. Global Neuroblastoma Chemotherapy Drugs Revenue by Region (2018-2023) & (US$ Million) Table 22. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Region (2018-2023) Table 23. Global Neuroblastoma Chemotherapy Drugs Revenue by Region (2024-2029) & (US$ Million) Table 24. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Region (2024-2029) Table 25. North America Neuroblastoma Chemotherapy Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 26. North America Neuroblastoma Chemotherapy Drugs Sales by Country (2018-2023) & (K Units) Table 27. North America Neuroblastoma Chemotherapy Drugs Sales by Country (2024-2029) & (K Units) Table 28. North America Neuroblastoma Chemotherapy Drugs Revenue by Country (2018-2023) & (US$ Million) Table 29. North America Neuroblastoma Chemotherapy Drugs Revenue by Country (2024-2029) & (US$ Million) Table 30. Europe Neuroblastoma Chemotherapy Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 31. Europe Neuroblastoma Chemotherapy Drugs Sales by Country (2018-2023) & (K Units) Table 32. Europe Neuroblastoma Chemotherapy Drugs Sales by Country (2024-2029) & (K Units) Table 33. Europe Neuroblastoma Chemotherapy Drugs Revenue by Country (2018-2023) & (US$ Million) Table 34. Europe Neuroblastoma Chemotherapy Drugs Revenue by Country (2024-2029) & (US$ Million) Table 35. Asia Pacific Neuroblastoma Chemotherapy Drugs Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million) Table 36. Asia Pacific Neuroblastoma Chemotherapy Drugs Sales by Region (2018-2023) & (K Units) Table 37. Asia Pacific Neuroblastoma Chemotherapy Drugs Sales by Region (2024-2029) & (K Units) Table 38. Asia Pacific Neuroblastoma Chemotherapy Drugs Revenue by Region (2018-2023) & (US$ Million) Table 39. Asia Pacific Neuroblastoma Chemotherapy Drugs Revenue by Region (2024-2029) & (US$ Million) Table 40. Latin America Neuroblastoma Chemotherapy Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 41. Latin America Neuroblastoma Chemotherapy Drugs Sales by Country (2018-2023) & (K Units) Table 42. Latin America Neuroblastoma Chemotherapy Drugs Sales by Country (2024-2029) & (K Units) Table 43. Latin America Neuroblastoma Chemotherapy Drugs Revenue by Country (2018-2023) & (US$ Million) Table 44. Latin America Neuroblastoma Chemotherapy Drugs Revenue by Country (2024-2029) & (US$ Million) Table 45. Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 46. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Country (2018-2023) & (K Units) Table 47. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Country (2024-2029) & (K Units) Table 48. Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue by Country (2018-2023) & (US$ Million) Table 49. Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue by Country (2024-2029) & (US$ Million) Table 50. Global Neuroblastoma Chemotherapy Drugs Sales (K Units) by Type (2018-2023) Table 51. Global Neuroblastoma Chemotherapy Drugs Sales (K Units) by Type (2024-2029) Table 52. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2018-2023) Table 53. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2024-2029) Table 54. Global Neuroblastoma Chemotherapy Drugs Revenue (US$ Million) by Type (2018-2023) Table 55. Global Neuroblastoma Chemotherapy Drugs Revenue (US$ Million) by Type (2024-2029) Table 56. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Type (2018-2023) Table 57. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Type (2024-2029) Table 58. Global Neuroblastoma Chemotherapy Drugs Price (US$/Unit) by Type (2018-2023) Table 59. Global Neuroblastoma Chemotherapy Drugs Price (US$/Unit) by Type (2024-2029) Table 60. Global Neuroblastoma Chemotherapy Drugs Sales (K Units) by Application (2018-2023) Table 61. Global Neuroblastoma Chemotherapy Drugs Sales (K Units) by Application (2024-2029) Table 62. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2018-2023) Table 63. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2024-2029) Table 64. Global Neuroblastoma Chemotherapy Drugs Revenue (US$ Million) by Application (2018-2023) Table 65. Global Neuroblastoma Chemotherapy Drugs Revenue (US$ Million) by Application (2024-2029) Table 66. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Application (2018-2023) Table 67. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Application (2024-2029) Table 68. Global Neuroblastoma Chemotherapy Drugs Price (US$/Unit) by Application (2018-2023) Table 69. Global Neuroblastoma Chemotherapy Drugs Price (US$/Unit) by Application (2024-2029) Table 70. Baxter Healthcare Corporation Information Table 71. Baxter Healthcare Description and Business Overview Table 72. Baxter Healthcare Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023) Table 73. Baxter Healthcare Neuroblastoma Chemotherapy Drugs Product Table 74. Baxter Healthcare Recent Developments/Updates Table 75. Ingenus Pharmaceuticals Corporation Information Table 76. Ingenus Pharmaceuticals Description and Business Overview Table 77. Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023) Table 78. Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Table 79. Ingenus Pharmaceuticals Recent Developments/Updates Table 80. ANI Pharmaceuticals Corporation Information Table 81. ANI Pharmaceuticals Description and Business Overview Table 82. ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023) Table 83. ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Table 84. ANI Pharmaceuticals Recent Developments/Updates Table 85. Teva Pharmaceuticals Corporation Information Table 86. Teva Pharmaceuticals Description and Business Overview Table 87. Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023) Table 88. Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Table 89. Teva Pharmaceuticals Recent Developments/Updates Table 90. Qilu Pharmaceutical Corporation Information Table 91. Qilu Pharmaceutical Description and Business Overview Table 92. Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023) Table 93. Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Product Table 94. Qilu Pharmaceutical Recent Developments/Updates Table 95. Pfizer Corporation Information Table 96. Pfizer Description and Business Overview Table 97. Pfizer Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023) Table 98. Pfizer Neuroblastoma Chemotherapy Drugs Product Table 99. Pfizer Recent Developments/Updates Table 100. Hikma Pharmaceuticals Corporation Information Table 101. Hikma Pharmaceuticals Description and Business Overview Table 102. Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023) Table 103. Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Table 104. Hikma Pharmaceuticals Recent Developments/Updates Table 105. Fresenius Kabi Corporation Information Table 106. Fresenius Kabi Description and Business Overview Table 107. Fresenius Kabi Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023) Table 108. Fresenius Kabi Neuroblastoma Chemotherapy Drugs Product Table 109. Fresenius Kabi Recent Developments/Updates Table 110. Accord Healthcare Corporation Information Table 111. Accord Healthcare Description and Business Overview Table 112. Accord Healthcare Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023) Table 113. Accord Healthcare Neuroblastoma Chemotherapy Drugs Product Table 114. Accord Healthcare Recent Developments/Updates Table 115. Viatris Corporation Information Table 116. Viatris Description and Business Overview Table 117. Viatris Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023) Table 118. Viatris Neuroblastoma Chemotherapy Drugs Product Table 119. Viatris Recent Developments/Updates Table 120. Key Raw Materials Lists Table 121. Raw Materials Key Suppliers Lists Table 122. Neuroblastoma Chemotherapy Drugs Distributors List Table 123. Neuroblastoma Chemotherapy Drugs Customers List Table 124. Neuroblastoma Chemotherapy Drugs Market Trends Table 125. Neuroblastoma Chemotherapy Drugs Market Drivers Table 126. Neuroblastoma Chemotherapy Drugs Market Challenges Table 127. Neuroblastoma Chemotherapy Drugs Market Restraints Table 128. Research Programs/Design for This Report Table 129. Key Data Information from Secondary Sources Table 130. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Neuroblastoma Chemotherapy Drugs Figure 2. Global Neuroblastoma Chemotherapy Drugs Market Value Comparison by Type (2023-2029) & (US$ Million) Figure 3. Global Neuroblastoma Chemotherapy Drugs Market Share by Type in 2022 & 2029 Figure 4. Cyclophosphamide Product Picture Figure 5. Cisplatin or Carboplatin Product Picture Figure 6. Vincristine Product Picture Figure 7. Doxorubicin (Adriamycin) Product Picture Figure 8. Etoposide Product Picture Figure 9. Other Product Picture Figure 10. Global Neuroblastoma Chemotherapy Drugs Market Value Comparison by Application (2023-2029) & (US$ Million) Figure 11. Global Neuroblastoma Chemotherapy Drugs Market Share by Application in 2022 & 2029 Figure 12. Hospital Figure 13. Clinic Figure 14. Other Figure 15. Global Neuroblastoma Chemotherapy Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029 Figure 16. Global Neuroblastoma Chemotherapy Drugs Market Size (2018-2029) & (US$ Million) Figure 17. Global Neuroblastoma Chemotherapy Drugs Sales (2018-2029) & (K Units) Figure 18. Global Neuroblastoma Chemotherapy Drugs Average Price (US$/Unit) & (2018-2029) Figure 19. Neuroblastoma Chemotherapy Drugs Report Years Considered Figure 20. Neuroblastoma Chemotherapy Drugs Sales Share by Manufacturers in 2022 Figure 21. Global Neuroblastoma Chemotherapy Drugs Revenue Share by Manufacturers in 2022 Figure 22. The Global 5 and 10 Largest Neuroblastoma Chemotherapy Drugs Players: Market Share by Revenue in 2022 Figure 23. Neuroblastoma Chemotherapy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022 Figure 24. Global Neuroblastoma Chemotherapy Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029 Figure 25. North America Neuroblastoma Chemotherapy Drugs Sales Market Share by Country (2018-2029) Figure 26. North America Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country (2018-2029) Figure 27. U.S. Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 28. Canada Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 29. Europe Neuroblastoma Chemotherapy Drugs Sales Market Share by Country (2018-2029) Figure 30. Europe Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country (2018-2029) Figure 31. Germany Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 32. France Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 33. U.K. Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 34. Italy Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 35. Russia Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 36. Asia Pacific Neuroblastoma Chemotherapy Drugs Sales Market Share by Region (2018-2029) Figure 37. Asia Pacific Neuroblastoma Chemotherapy Drugs Revenue Market Share by Region (2018-2029) Figure 38. China Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 39. Japan Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 40. South Korea Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 41. India Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 42. Australia Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 43. Taiwan Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 44. Indonesia Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 45. Thailand Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 46. Malaysia Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 47. Philippines Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 48. Latin America Neuroblastoma Chemotherapy Drugs Sales Market Share by Country (2018-2029) Figure 49. Latin America Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country (2018-2029) Figure 50. Mexico Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 51. Brazil Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 52. Argentina Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 53. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Market Share by Country (2018-2029) Figure 54. Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country (2018-2029) Figure 55. Turkey Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 56. Saudi Arabia Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 57. U.A.E Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 58. Global Sales Market Share of Neuroblastoma Chemotherapy Drugs by Type (2018-2029) Figure 59. Global Revenue Market Share of Neuroblastoma Chemotherapy Drugs by Type (2018-2029) Figure 60. Global Neuroblastoma Chemotherapy Drugs Price (US$/Unit) by Type (2018-2029) Figure 61. Global Sales Market Share of Neuroblastoma Chemotherapy Drugs by Application (2018-2029) Figure 62. Global Revenue Market Share of Neuroblastoma Chemotherapy Drugs by Application (2018-2029) Figure 63. Global Neuroblastoma Chemotherapy Drugs Price (US$/Unit) by Application (2018-2029) Figure 64. Neuroblastoma Chemotherapy Drugs Value Chain Figure 65. Neuroblastoma Chemotherapy Drugs Production Process Figure 66. Channels of Distribution (Direct Vs Distribution) Figure 67. Distributors Profiles Figure 68. Bottom-up and Top-down Approaches for This Report Figure 69. Data Triangulation Figure 70. Key Executives Interviewed

Baxter Healthcare Ingenus Pharmaceuticals ANI Pharmaceuticals Teva Pharmaceuticals Qilu Pharmaceutical Pfizer Hikma Pharmaceuticals Fresenius Kabi Accord Healthcare Viatris